Rofenaid in the control of Pasteurella anatipestifer and Escherichia coli infections in ducklings.

In a series of controlled battery trials, Rofenaid (at doses ranging from 0.02 to 0.12% active drug in feed) was administered to ducklings infected experimentally with Pasteurella anatipestifer and Escherichia coli strains. Against P. anatipestifer, Rofenaid at 0.02 to 0.12% levels in feed either prevented or reduced mortality, gross lesions, and bacterial isolations. Furthermore, the weight gain and feed conversion of infected Rofenaid-medicated ducklings were superior to those of uninfected unmedicated controls in two out of three trials. Against E. coli, Rofenaid at 0.02 to 0.08% levels in feed either prevented or reduced mortality, gross lesions, and bacterial isolations. Weight gain and feed conversion of infected Rofenaid-medicated ducklings were also superior to those of uninfected unmedicated controls in two out of three trials. It appears that Rofenaid, at a 0.02-0.08% level, controls infections in ducklings caused by P. anatipestifer and E. coli strains sensitive to this compound.

Prophylactic and therapeutic activity of Rofenaid-40A in an experimental Escherichia coli airsac infection in chickens.

Rofenaid at a 0.02% dose level in feed was effective prophylactically and therapeutically against an experimentally induced Escherichia coli airsac infection in chickens. The activity of Rofenaid compared very favorably with that of the approved dose level of NF-180. Furthermore, the prophylactic use of Rofenaid did not interfere with the therapeutic efficacy of NF-180.

Evaluation of a cuprimyxin-hydrocortisone acetate suspension in the treatment of otitis externa in dogs and cats.

The therapeutic efficacy of a 0.5% cuprimyxin plus 1% hydrocortisone acetate-water-base suspension was evaluated in 130 clinical cases of otitis externa in dogs and cats in various geographic areas of the United States. The otic microbial flora was studied before treatment in 125 (96%) of the dogs and cats, with multiple isolates recovered from mated from 70%, yeasts from 65%, and fungi from 5% of the animals. Evens though multiple drug reistance was frequently observed in the bacterial flora, all bacteria and yeast isolates were sensitive to cuprimyxin. Of the 130 treated animals, a statistically significant (P less than 0.01) favorable response was obtained in 84,6% and no response in 13;1%; in2.3%, the condition became worse. An adverse reaction (pain at the time of first application) was observed in 1 (0.8%) animal.

Influence of rofenaid-40 feed medication on an experimental Salmonella infection in chickens.

Rofenaid-40 administered at 0.02% in feed to chickens experimentally infected with Salmonella typhimurium resulted in less colonization and shedding of S. typhimurium than in unmedicated chickens. The antibacterial sensitivity pattern of S. typhimurium isolated from infected birds had not changed after exposure to Rofenaid for 56 days.

Sphaerophorus necrophorus: laboratory model for the evaluation of chemotherapeutic agents in mice.

Severe necro-purulent lesions were induced in mice following parenteral inoculation of Sphaerophorus necrophorus. Gross and histological changes observed in the lung, liver, and foot pad of infected mice were similar to those occurring naturally in cattle. The lesions could be prevented, cured or significantly reduced by the administration of chemotherapeutic agents such as sulfonamides, potentiated sulfonamide and antibiotics. The application of this novel laboratory model infection in the primary evaluation of potential antibacterial agents is discussed.